CRAFA
PEPTIDE & COMPOUND ANALYSIS

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-2059
Issued: 2026-10-13

PRODUCT IDENTIFICATION

PRODUCT
Retatrutide + Cagrilintide 5 mg + 5 mg

SKU / INTERNAL CODE
CRF-2026-2059

PRESENTATION
Lyophilised powder, 10 mg vial

BATCH NUMBER
LOT-2610-2059

CLIENT
veltispeptides.mx

SAMPLE RECEIVED
2026-10-08

ANALYSIS DATE
2026-10-11

PRODUCTION DATE
2026-10-06

ISSUED
2026-10-13

EXPIRY / RETEST
2028-10-13

MOLECULAR FORMULA
Blend (C221H342N46O68 + C194H312N54O59S2)

MOLECULAR WEIGHT
4731.36 / 4409.0

CAS NUMBER
2381089-83-2 / 1415456-99-3

ANALYTICAL METHOD

PANEL
SILVER - HPLC-UV + LC-MS/MS + ICP-MS (Pb/As/Cd/Hg) + LAL endotoxin

METHOD
RP-HPLC-UV 214 nm · LC-MS/MS ESI Q-TOF · ICP-MS · LAL kinetic chromogenic (USP <85>)

INSTRUMENT
Thermo Q-Exactive · Agilent 7900 ICP-MS · Charles River Endosafe nexgen-PTS

Column: C4 2.1×100mm | Temperature: 60°C | Mobile phase: 0.1% TFA H2O / ACN | Flow: 0.3 mL/min | Retention time: 14.2 / 12.1 min

CRAFA
PEPTIDE & COMPOUND ANALYSIS

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-2059
Issued: 2026-10-13

1. PURITY & ASSAY - RP-HPLC-UV (214 nm)

Test	Specification	Result	Status
HPLC Purity	≥98.0%	99.3%	PASS
Quantity (total)	95.0-105.0%	9.97 mg (99.7%)	PASS
Ratio Check (1:1)	±5%	5.01 / 4.96 mg	PASS

2. LC-MS/MS STRUCTURAL CONFIRMATION

Test	Reported data	Status
Retatrutide - Theoretical [M+H]+	4732.4 | Observed: 4732.8 | Δ +0.40 Da	PASS
Cagrilintide - Theoretical [M+H]+	4410.0 | Observed: 4410.3 | Δ +0.30 Da	PASS
Sequence Coverage	Retatrutide 97% · Cagrilintide 96%	PASS
Key fragments	RT b21 2431.2 / y27 3142.6 · Cag b14 1651.8 / y19 2214.1	PASS
Modifications	RT C20 diacid + Cag C16 fatty acid side chains both intact	PASS
Cross-contamination	none - both masses baseline-resolved	PASS

RESEARCH USE ONLY - NOT FOR HUMAN OR VETERINARY USE

CRAFA
PEPTIDE & COMPOUND ANALYSIS

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-2059
Issued: 2026-10-13

3. HEAVY METALS - ICP-MS (USP <232>/<233>)

Test	Specification	Result	Status
Pb		<0.05 µg/g	PASS
As		<0.10 µg/g	PASS
Cd		<0.02 µg/g	PASS
Hg		<0.01 µg/g	PASS

4. ENDOTOXIN - LAL kinetic chromogenic (USP <85>)

Test	Reported data	Status
Result	<1.0 EU/mg limit | 0.26 EU/mg | PPC recovery 83%	PASS

FINAL BATCH RESULT

PASS - Conforms to specifications

ANALYST NOTES

Triple agonist + amylin analogue. Both components investigational. No aggregation in co-lyophilised matrix (<0.4% SEC).

crafa

CRAFA